Immune Microenvironment and the Effect of Vascular Endothelial Growth Factor Inhibition in Hepatocellular Carcinoma

Area of Science:

• Oncology
• Immunology
• Angiogenesis Research

Background:

• Systemic therapy for unresectable hepatocellular carcinoma (HCC) has advanced with targeted therapies and immune checkpoint inhibitors.
• Vascular Endothelial Growth Factor (VEGF) signaling is crucial for cancer growth and angiogenesis in HCC.
• Current treatments include multi-kinase inhibitors and immunotherapies like atezolizumab + bevacizumab.

Purpose of the Study:

• To review the role of VEGF in the tumor immune microenvironment and cancer immune cycle in HCC.
• To outline potential immune regulatory mechanisms of VEGF.
• To clarify the latest treatment strategies maximizing efficacy through dual inhibition of angiogenesis and immune-related molecules.

Main Methods:

• Literature review of systemic therapies for unresectable HCC.
• Analysis of VEGF's role in tumor immunology and angiogenesis.
• Discussion of current and emerging treatment strategies targeting VEGF.

Main Results:

• VEGF inhibition is recognized for its anti-angiogenic effects and impact on the cancer-immune cycle.
• Atezolizumab + bevacizumab therapy highlights the efficacy of combining immunotherapy with VEGF inhibition.
• VEGF influences the tumor immune microenvironment and cancer immune cycle in HCC.

Conclusions:

• VEGF plays a significant role in HCC progression and the tumor immune microenvironment.
• Dual inhibition strategies targeting both angiogenesis and immune pathways show promise for unresectable HCC.
• Understanding VEGF's immune regulatory mechanisms is key to optimizing future HCC treatments.